Profile: Biogen Idec Inc (BIIB.O)
6 Dec 2013
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. During the year ended December 31, 2011, the Company began making AVONEX PEN available in the European Union (EU) and Canada. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the United States to treat Crohn’s disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). In January 2012, the United States Food and Drug Association (FDA) approved the inclusion of anti-JCV antibody status as an additional factor in stratifying patients for developing PML in the United States product label for TYSABRI. In August 2011, its JC virus assay became available in the United States.
The Company’s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. In April 2011, the FDA approved RITUXAN, in combination with corticosteroids, as a treatment for adults with Wegener’s granulomatosis and microscopic polyangiitis, two forms of ANCA-associated vasculitis. In January 2011, the FDA approved RITUXAN as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with RITUXAN plus chemotherapy.
FAMPYRA addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. During 2011, it launched FAMPYRA in Australia, Denmark, Germany, Norway and the United Kingdom. It has a license from Acorda Therapeutics, Inc. to develop and commercialize FAMPYRA in all markets outside the United States. FUMADERM is approved for the treatment of psoriasis in Germany.
Other Sources of Revenue
The Company’s source of other revenue is derived from royalties received on sales by its licensees of other products covered under patents, which it owns. Its royalty revenues are dependent upon its licensees’ sales of licensed products. In addition, the expiration or invalidation of any underlying patents could reduce or eliminate the royalty revenues derived from such patents. Royalties on sales of ANGIOMAX by The Medicines Company (TMC) represents its source of other revenue. TMC markets ANGIOMAX in the United States and the European Union for use as an anticoagulant in patients undergoing percutaneous coronary intervention.
Research and Development Programs
The Company focuses to research and development opportunities and business development activity. It is conducting clinical studies to advance the development of pharmaceutical products and to explore the utility of its existing products in treating disorders beyond those approved in their labels. The Company’s product for neurology include BG-12, Daclizumab, Dexpramipexole, PEGylated interferon beta 1a, TYSABRI, BG-12, Anti-LINGO, BIIB037, Neublastin, BIIB053 and BIIB054. Its product candidates for hemophilia include Factor VIII Fc and Factor IX Fc; for immunology include Anti-TWEAK, Anti-CD40 Ligand and Syk inhibitor, and other product candidate include GA101.
Daclizumab is a monoclonal antibody, which is being tested in relapsing MS. Dexpramipexole is an orally administered small molecule in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). PEGylated interferon beta-1a is designed to prolong the effects and reduce the dosing frequency of interferon beta-1a. Factor VIII is a fusion protein, which is being tested in hemophilia A. Factor IX is a fusion protein, which is being tested in hemophilia B, a disorder in which blood clotting is impaired. It collaborates with Genentech, Inc., a wholly owned member of the Roche Group, on the development and commercialization of GA101, a monoclonal antibody.
The Company competes with Teva Pharmaceutical Industries Ltd., Sanofi-Aventis, Merck Serono, Pfizer Inc., Bayer Schering Pharma AG, Novartis AG, Genzyme Corporation, Cephalon, GenMab, GlaxoSmithKline, Johnson & Johnson, Abbott Laboratories, Amgen, Inc., UCB, S.A., Bristol-Myers Squibb Company and Roche Group.
Biogen Idec Inc
133 Boston Post Road
CAMBRIDGE MA 02142